Michael H Tomasson
Overview
Explore the profile of Michael H Tomasson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
9995
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vasileva A, Flores L, Vasilyev M, Buckman M, DeRuisseau L, Tomasson M, et al.
Am J Physiol Regul Integr Comp Physiol
. 2024 Dec;
328(1):R133-R144.
PMID: 39636660
Urethane is widely used for its ability to induce prolonged anesthesia. Variability in previously reported cardiovascular parameters in murine models makes it challenging to definitively evaluate the cardiovascular effects of...
2.
Greteman B, Tomasson M, Kahl A, Wahlen M, Bates M, Strouse C, et al.
Cancer Causes Control
. 2024 Nov;
PMID: 39586915
Purpose: It is important to understand racial inequities in multiple myeloma treatment and survival, particularly in the Midwest where clear differences exist in cancer incidence and mortality. Since age and...
3.
Tomasson M, Iida S, Niesvizky R, Mohty M, Bahlis N, Martinez-Lopez J, et al.
Hemasphere
. 2024 Jul;
8(7):e136.
PMID: 39055646
No abstract available.
4.
Bahlis N, Costello C, Raje N, Levy M, Dholaria B, Solh M, et al.
Nat Med
. 2023 Oct;
29(10):2570-2576.
PMID: 37783970
Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial...
5.
Lesokhin A, Tomasson M, Arnulf B, Bahlis N, Prince H, Niesvizky R, et al.
Nat Med
. 2023 Aug;
29(9):2259-2267.
PMID: 37582952
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after...
6.
Zhang Z, Kalra H, Delzell M, Jedlicka C, Vasilyev M, Vasileva A, et al.
J Appl Physiol (1985)
. 2023 Mar;
134(5):1207-1215.
PMID: 36958346
Chamber exposures are commonly used to evaluate the physiological and pathophysiological consequences of intermittent hypoxia in animal models. Researchers in this field use both commercial and custom-built chambers in their...
7.
Bates M, Vasileva A, Flores L, Pryakhina Y, Buckman M, Tomasson M, et al.
Am J Physiol Heart Circ Physiol
. 2023 Feb;
324(4):H542-H552.
PMID: 36800509
This meta-analysis, which consisted of a scoping review and retrospective medical record review, is focused on potential sex differences in cardiovascular diseases in patients with Down syndrome. We limited our...
8.
Dhakal P, Bates M, Tomasson M, Sutamtewagul G, Dupuy A, Bhatt V
Blood Rev
. 2022 Dec;
59:101036.
PMID: 36549969
Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with a DNA hypomethylating agent or low dose cytarabine, results in high rates of initial responses in patients with...
9.
Amaza I, Kalra H, Eberlein M, Jethava Y, McDonell J, Wolfe B, et al.
J Appl Physiol (1985)
. 2021 May;
131(2):788-793.
PMID: 33955261
Diagnosing the cause of hypoxemia and dyspnea can be complicated in complex patients with multiple comorbidities. This "Case Study in Physiology" describes an man with obesity admitted to the hospital...
10.
Pottebaum E, Warmoth A, Ayyappan S, Dickens D, Jethava Y, Modi A, et al.
Exerc Sport Sci Rev
. 2021 Apr;
49(3):205-212.
PMID: 33927164
Hematopoietic stem cell transplant (HSCT) is a potentially curative treatment for hematopoietic malignancies, complicated by decreased performance status and quality of life. Exercise therapy improves outcomes in HSCT, but several...